News
OCUL
10.83
+2.46%
0.26
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
Barchart · 1d ago
Weekly Report: what happened at OCUL last week (1028-1101)?
Weekly Report · 2d ago
OCULAR THERAPEUTIX INC <OCUL.O>: JEFFERIES RAISES TARGET PRICE TO $16 FROM $11
Reuters · 10/29 11:45
U.S. RESEARCH ROUNDUP- Coinbase Global, Meta, Union Pacific
Reuters · 10/29 06:41
Weekly Report: what happened at OCUL last week (1021-1025)?
Weekly Report · 10/28 11:00
Piper Sandler Remains a Buy on Ocular Therapeutix (OCUL)
TipRanks · 10/22 10:55
Weekly Report: what happened at OCUL last week (1014-1018)?
Weekly Report · 10/21 10:57
Optimistic Buy Rating for Ocular Therapeutix Amid Accelerated SOL-1 Study Progress
TipRanks · 10/17 15:05
Ocular Therapeutix Price Target Announced at $22.00/Share by Scotiabank
Dow Jones · 10/16 14:14
Scotiabank Initiates Coverage On Ocular Therapeutix with Sector Outperform Rating, Announces Price Target of $22
Benzinga · 10/16 14:03
Disney initiated, Cisco upgraded: Wall Street’s top analyst calls
TipRanks · 10/16 13:35
Ocular Therapeutix initiated with an Outperform at Scotiabank
TipRanks · 10/16 11:45
Ocular Therapeutix Price Target Maintained With a $14.00/Share by HC Wainwright & Co.
Dow Jones · 10/16 11:02
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $14 Price Target
Benzinga · 10/16 10:52
Ocular Therapeutix’s Promising Clinical Advancements and Strategic Trials Drive Buy Rating
TipRanks · 10/16 10:25
Buy Rating on Ocular Therapeutix: Accelerated Phase 3 Trial Enrollment and Promising 2025 Outlook
TipRanks · 10/16 08:55
Ocular Therapeutix management to meet with Piper Sandler
TipRanks · 10/15 19:50
Ocular Therapeutix announces accelerated timelines for trial of AXPAXLI in wet AMD
Seeking Alpha · 10/15 13:28
Ocular Therapeutix Fast-Tracks SOL-1 Registrational Trial For Wet AMD, Topline Data Expected In Late 2025
Benzinga · 10/15 11:40
Ocular announces accelerated timelines for SOL-1 registrational trial
TipRanks · 10/15 11:36
More
Webull provides a variety of real-time OCUL stock news. You can receive the latest news about Ocular Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. It is also developing two other clinical-stage assets, OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease. It is conducting a pivotal Phase III clinical trial to evaluate AXPAXLI for the treatment of wet AMD. Its clinical portfolio also includes PAXTRAVA, which is in Phase III clinical development for the treatment of primary open-angle glaucoma (OAG) or ocular hypertension (OHT).